Bicocca Open Archive

Logo unimib boa
CAZZANIGA, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.567
AS - Asia 16.833
EU - Europa 12.360
SA - Sud America 2.557
AF - Africa 397
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 24
Totale 61.772
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.327
SG - Singapore 6.023
CN - Cina 3.411
IT - Italia 2.605
HK - Hong Kong 2.499
VN - Vietnam 2.414
RU - Federazione Russa 2.048
BR - Brasile 1.894
IE - Irlanda 1.394
DE - Germania 1.391
SE - Svezia 1.369
CA - Canada 1.019
UA - Ucraina 782
GB - Regno Unito 640
FR - Francia 595
IN - India 468
FI - Finlandia 367
BD - Bangladesh 291
AT - Austria 247
AR - Argentina 245
ID - Indonesia 238
KR - Corea 219
TR - Turchia 216
NL - Olanda 186
IQ - Iraq 185
ES - Italia 184
PK - Pakistan 141
MX - Messico 139
JP - Giappone 133
ZA - Sudafrica 121
SA - Arabia Saudita 110
PL - Polonia 108
EC - Ecuador 97
CO - Colombia 82
DK - Danimarca 78
PH - Filippine 78
VE - Venezuela 76
BE - Belgio 68
CH - Svizzera 63
UZ - Uzbekistan 59
PY - Paraguay 44
EG - Egitto 43
CL - Cile 42
MA - Marocco 42
CZ - Repubblica Ceca 39
JO - Giordania 37
KE - Kenya 37
MY - Malesia 35
PE - Perù 33
TN - Tunisia 31
ET - Etiopia 30
AE - Emirati Arabi Uniti 29
GR - Grecia 28
IL - Israele 27
AU - Australia 25
KZ - Kazakistan 24
PT - Portogallo 24
AZ - Azerbaigian 22
BG - Bulgaria 22
NP - Nepal 22
LB - Libano 21
UY - Uruguay 21
DZ - Algeria 20
LT - Lituania 20
TW - Taiwan 17
EU - Europa 16
IR - Iran 16
JM - Giamaica 16
OM - Oman 16
RO - Romania 16
TH - Thailandia 16
BO - Bolivia 15
AL - Albania 14
PA - Panama 12
SN - Senegal 12
CR - Costa Rica 11
DO - Repubblica Dominicana 11
NO - Norvegia 11
AO - Angola 10
KG - Kirghizistan 9
NG - Nigeria 9
BH - Bahrain 8
HU - Ungheria 8
MU - Mauritius 8
NI - Nicaragua 8
RS - Serbia 8
BY - Bielorussia 7
HR - Croazia 7
SY - Repubblica araba siriana 7
TT - Trinidad e Tobago 7
KW - Kuwait 6
LV - Lettonia 6
NZ - Nuova Zelanda 6
SK - Slovacchia (Repubblica Slovacca) 6
EE - Estonia 5
GE - Georgia 5
LK - Sri Lanka 5
LY - Libia 5
QA - Qatar 5
RE - Reunion 5
Totale 61.677
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.634
Singapore 3.492
Ashburn 2.594
Hong Kong 2.446
Fairfield 2.293
Woodbridge 2.114
Houston 1.682
Dublin 1.360
San Jose 1.357
Chandler 1.252
Wilmington 1.068
Seattle 893
Frankfurt am Main 850
Cambridge 799
Jacksonville 759
Milan 741
Ho Chi Minh City 740
New York 738
Toronto 701
Dearborn 605
Santa Clara 579
Hanoi 524
Beijing 513
Chicago 506
Princeton 493
Los Angeles 492
The Dalles 399
Hefei 374
Dallas 352
Lauterbourg 257
Lawrence 239
Nanjing 233
Altamura 224
Moscow 216
Shanghai 215
Seoul 202
Buffalo 189
Vienna 188
São Paulo 180
Jakarta 167
Council Bluffs 154
San Diego 153
Helsinki 151
Lachine 124
Munich 111
Orem 110
Guangzhou 97
London 92
Warsaw 89
Nuremberg 88
Rome 87
Tokyo 85
Montreal 81
Denver 80
Dong Ket 80
Nanchang 80
Andover 79
Lissone 79
Da Nang 76
Haiphong 76
Baghdad 75
Brooklyn 75
Shenyang 67
Chennai 65
Boardman 64
Changsha 64
Tianjin 64
Rio de Janeiro 63
Fuzhou 62
Brussels 61
Salt Lake City 59
Phoenix 56
Hebei 55
Jinan 53
Paris 52
Stockholm 52
Zurich 51
Johannesburg 49
Poplar 49
Tashkent 48
Atlanta 46
Amsterdam 44
Biên Hòa 43
Hải Dương 43
Turku 43
Lappeenranta 41
Norwalk 41
Zhengzhou 41
Belo Horizonte 39
Jeddah 39
San Francisco 39
Dhaka 38
Ha Long 38
Brasília 37
Lahore 37
Hangzhou 36
Manchester 36
Mumbai 36
Riyadh 36
Boston 35
Totale 40.604
Salva come PNG Salva come JPEG
Nome #
Four Additional Doses of PEG-L-Asparaginase during the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study 523
BEYOND THE TUMOUR: CHILDHOOD CANCER PREDISPOSING SYNDROMES [Guardare oltre il tumore: le cancer-predisposingsyndrome in età pediatrica] 520
Prenatal Origin of Pediatric Leukemia: Lessons From Hematopoietic Development 507
Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche 469
First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia 454
NIPBL: a new player in myeloid cells differentiation 443
Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies 440
IKZF1 plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric b-cell precursor acute lymphoblastic leukemia 435
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 427
Hodgkin lymphoma in a patient with mosaic trisomy 18: First clinical observation 421
Clinical features and outcome of SIL/TAL1-positive t-cell acute lymphoblastic leukemia in children and adolescents: A 10-year experience of the AIEOP group 420
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia 406
A simple RNA target capture NGS strategy for fusion genes assessment in the diagnostics of pediatric B-cell acute lymphoblastic leukemia 401
Biallelic PI4KA Mutations Disrupt B-Cell Metabolism and Cause B-Cell Lymphopenia and Hypogammaglobulinemia 392
Phenotypical and Functional Characterization of Mesenchymal Stem Cells Derived From Patients Affected by Schwachman-Diamond Syndrome 381
Unravelling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis 374
Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency 373
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 372
Idiopathic erythrocytosis: a germline disease? 369
The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL 364
Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection 362
Activin A contributes to the definition of a pro-oncogenic bone marrow microenvironment in t(12;21) preleukemia 361
Hematopoietic Stem Cell (HSC)-Independent Progenitors Are Susceptible to Mll-Af9-Induced Leukemic Transformation 358
Good outcome for very high risk adult B-cell acute lymphoblastic leukaemia carrying genetic abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if promptly submitted to allogeneic transplantation, after obtaining a good molecular remission 356
TNFRSF13C (BAFFR) positive blasts persist after early treatment and at relapse in childhood B-cell precursor acute lymphoblastic leukaemia 347
Antileukemic efficacy of BET inhibitor in a preclinical mouse model of MLL-AF4 + infant ALL 336
NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLL-r B-ALL by regulating NR3C1 expression 329
Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia 328
Cytoskeletal Regulatory Gene Expression and Migratory Properties of B Cell Progenitors are Affected by the ETV6-RUNX1 Rearrangement 322
Two siblings presenting with novel ADA2 variants, lymphoproliferation, persistence of large granular lymphocytes, and T-cell perturbations 321
The bone marrow niche in b-cell acute lymphoblastic leukemia: The role of microenvironment from pre-leukemia to overt leukemia 321
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting 319
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 314
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 308
Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model 308
Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome 308
Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: An international collaborative study 307
Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia 306
Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection 305
CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia 302
SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia 302
Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants 300
High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia 299
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia 296
Efficient detection of leukemia-related fusion transcripts by multiplex PCR applied on a microelectronic platform 293
High EVI1 Expression due to NRIP1/EVI1 Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case 292
PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells 290
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia 288
A novel homozygous disruptive PRF1 variant (K285Sfs*4) causes very early-onset of familial hemophagocytic lymphohystiocytosis type 2 288
Clinico-biologic features of 5202 acute lymphoblastic leukemia patients enrolled in the Italian AIEOP and GIMEMA Protocols and stratified in age-cohorts 286
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial 283
Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia 282
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120 278
Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype 278
Characterization of children with FLT3-ITD acute myeloid leukemia: A report from the AIEOP AML-2002 study group 277
Abnormal B-Cell Maturation and Increased Transitional B Cells in CBL Syndrome 275
Predictive factors of relapse and survival in childhood acute myeloid leukemia: Role of minimal residual disease 275
Antibody Deficiency in Patients with Biallelic KARS1 Mutations 271
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation 270
PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5 269
LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients 268
Mesenchymal stem cells from Shwachman-Diamond syndrome patients display normal functions and do not contribute to hematological defects 267
Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? 267
Nodal monoclonal CD5-positive B-lymphocytosis and toxoplasma lymphadenitis: Another variant in the spectrum of infectious lymphadenitis in patients with chronic leukemia/small lymphocytic lymphoma 266
Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL 266
PTEN opposes negative selection and enables oncogenic transformation of pre-B cells 265
Fine Tuning of Surface CRLF2 Expression and Its Associated Signalling Profile in Childhood B Cell Precursor Acute Lymphoblastic Leukemia 264
Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement 264
Acute myeloid leukemia in Baraitser–Winter cerebrofrontofacial syndrome 263
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia 263
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome 262
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000 261
The KMT2A recombinome of acute leukemias in 2023 259
Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia 259
Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response 258
Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia 257
Modeling Cornelia de Lange syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation 257
Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study 256
DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4 256
What is the relevance of Ikaros gene deletions as prognostic marker in pediatric Philadelphia negative B-cell precursor acute lymphoblastic leukemia? 256
Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment 255
Metabolic gatekeeper function of B-lymphoid transcription factors 255
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 254
IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia 253
Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition 250
Novel Chimeric Transcripts Involving PAX5 in B-Cell Precursor ALL 249
Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis 249
Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia". 248
Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial 248
High incidence and unique features of antigen receptor gene rearrangements in TEL-AML1-positive leukemias 247
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols 246
Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia 244
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study 243
Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia 243
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations 240
CyclinD1 Down-Regulation and Increased Apoptosis Are Common Features of Cohesinopathies 239
More than an ‘atypical’ phenotype: dual molecular diagnosis of autoimmune lymphoproliferative syndrome and Becker muscular dystrophy 238
Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia 238
Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening 237
The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis 237
Totale 30.848
Salva come PNG Salva come JPEG
Categoria #
all - tutte 203.998
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 203.998
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021753 0 0 0 0 0 0 0 0 0 0 350 403
2021/20223.278 232 342 419 237 256 271 123 177 208 230 227 556
2022/20235.119 663 1.625 374 426 282 793 67 292 332 31 154 80
2023/20244.081 119 130 173 185 528 1.087 816 152 357 85 81 368
2024/20259.831 466 1.067 552 447 866 311 662 292 1.069 1.516 861 1.722
2025/202622.653 3.009 1.663 1.751 2.696 2.926 1.262 3.118 1.250 1.825 2.067 1.086 0
Totale 62.986